Logo image of AVBP

ARRIVENT BIOPHARMA INC (AVBP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AVBP - US04272N1028 - Common Stock

21.97 USD
-0.32 (-1.44%)
Last: 12/26/2025, 8:00:00 PM
21.97 USD
0 (0%)
After Hours: 12/26/2025, 8:00:00 PM
Fundamental Rating

3

Overall AVBP gets a fundamental rating of 3 out of 10. We evaluated AVBP against 530 industry peers in the Biotechnology industry. AVBP has a great financial health rating, but its profitability evaluates not so good. AVBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AVBP had negative earnings in the past year.
AVBP had a negative operating cash flow in the past year.
AVBP Yearly Net Income VS EBIT VS OCF VS FCFAVBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

AVBP's Return On Assets of -46.36% is in line compared to the rest of the industry. AVBP outperforms 53.21% of its industry peers.
AVBP has a better Return On Equity (-49.64%) than 65.85% of its industry peers.
Industry RankSector Rank
ROA -46.36%
ROE -49.64%
ROIC N/A
ROA(3y)-30.66%
ROA(5y)N/A
ROE(3y)-32.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVBP Yearly ROA, ROE, ROICAVBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

AVBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVBP Yearly Profit, Operating, Gross MarginsAVBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AVBP has more shares outstanding
There is no outstanding debt for AVBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVBP Yearly Shares OutstandingAVBP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
AVBP Yearly Total Debt VS Total AssetsAVBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 23.12 indicates that AVBP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 23.12, AVBP belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
AVBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.12
ROIC/WACCN/A
WACCN/A
AVBP Yearly LT Debt VS Equity VS FCFAVBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 14.90 indicates that AVBP has no problem at all paying its short term obligations.
The Current ratio of AVBP (14.90) is better than 91.51% of its industry peers.
AVBP has a Quick Ratio of 14.90. This indicates that AVBP is financially healthy and has no problem in meeting its short term obligations.
AVBP has a better Quick ratio (14.90) than 91.51% of its industry peers.
Industry RankSector Rank
Current Ratio 14.9
Quick Ratio 14.9
AVBP Yearly Current Assets VS Current LiabilitesAVBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AVBP have decreased strongly by -61.70% in the last year.
EPS 1Y (TTM)-61.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVBP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.79% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-72.25%
EPS Next 2Y-24.43%
EPS Next 3Y-4.6%
EPS Next 5Y25.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVBP Yearly Revenue VS EstimatesAVBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
AVBP Yearly EPS VS EstimatesAVBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AVBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVBP Price Earnings VS Forward Price EarningsAVBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVBP Per share dataAVBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

AVBP's earnings are expected to decrease with -4.60% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.43%
EPS Next 3Y-4.6%

More info and screens

0

5. Dividend

5.1 Amount

AVBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (12/26/2025, 8:00:00 PM)

After market: 21.97 0 (0%)

21.97

-0.32 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-01 2026-03-01/bmo
Inst Owners90.81%
Inst Owner Change14.88%
Ins Owners3.13%
Ins Owner Change3.83%
Market Cap906.92M
Revenue(TTM)N/A
Net Income(TTM)-151.40M
Analysts85.88
Price Target41.57 (89.21%)
Short Float %19.65%
Short Ratio20.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.24%
Min EPS beat(2)-25.38%
Max EPS beat(2)-3.09%
EPS beat(4)1
Avg EPS beat(4)-46.49%
Min EPS beat(4)-180.53%
Max EPS beat(4)23.03%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.62%
PT rev (3m)5.03%
EPS NQ rev (1m)-2.98%
EPS NQ rev (3m)-12.3%
EPS NY rev (1m)-6.18%
EPS NY rev (3m)-6.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.97
P/tB 2.97
EV/EBITDA N/A
EPS(TTM)-4.24
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0
BVpS7.39
TBVpS7.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.36%
ROE -49.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.66%
ROA(5y)N/A
ROE(3y)-32.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.9
Quick Ratio 14.9
Altman-Z 23.12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.07%
EPS Next Y-72.25%
EPS Next 2Y-24.43%
EPS Next 3Y-4.6%
EPS Next 5Y25.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-73.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-57.4%
EBIT Next 3Y-16.07%
EBIT Next 5YN/A
FCF growth 1Y-157.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.11%
OCF growth 3YN/A
OCF growth 5YN/A

ARRIVENT BIOPHARMA INC / AVBP FAQ

Can you provide the ChartMill fundamental rating for ARRIVENT BIOPHARMA INC?

ChartMill assigns a fundamental rating of 3 / 10 to AVBP.


What is the valuation status for AVBP stock?

ChartMill assigns a valuation rating of 0 / 10 to ARRIVENT BIOPHARMA INC (AVBP). This can be considered as Overvalued.


How profitable is ARRIVENT BIOPHARMA INC (AVBP) stock?

ARRIVENT BIOPHARMA INC (AVBP) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AVBP stock?

The Earnings per Share (EPS) of ARRIVENT BIOPHARMA INC (AVBP) is expected to decline by -72.25% in the next year.